The FDA Alert on Serotonin Syndrome With Use of Triptans Combined With Selective Serotonin Reuptake Inhibitors or Selective Serotonin‐Norepinephrine Reuptake Inhibitors: American Headache Society Position Paper
Randolph W. Evans(University of Vermont), Gretchen E. Tietjen(University of Vermont), Stewart J. Tepper(New England Institute for Neurology and Headache), Christina Sun‐Edelstein(St Vincent's Hospital Melbourne), Robert E. Shapiro(University of Vermont)
Cited by 126
Related Papers
Drug-induced serotonin syndrome: a review
|Expert Opinion on Drug Safety|2008|169
Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study
|Headache The Journal of Head and Face Pain|2022|150
Foods and Supplements in the Management of Migraine Headaches
|Clinical Journal of Pain|2009|146
Risk of medication overuse headache across classes of treatments for acute migraine
|The Journal of Headache and Pain|2016|115
Role of magnesium in the pathogenesis and treatment of migraine
|Expert Review of Neurotherapeutics|2009|100